Sunflower Pharmaceuticals Group Co Ltd

Sunflower Pharmaceutical Group's controlling subsidiary, Sunflower Pharmaceutical Group Hengshui Defeier Co., Ltd., recently received a drug registration certificate for glucosamine sulfate capsules issued by the National Medical Products Administration. The drug is registered as a Category 4 chemical medicine, classified as an over-the-counter product in Class A, with specifications of 0.25 grams calculated as glucosamine sulfate or 0.314 grams calculated as glucosamine sulfate sodium chloride, indicated for primary and secondary osteoarthritis. The company said the approval will further enrich its rheumatology and bone disease product pipeline in the elderly care segment. Through the implementation of its blockbuster single product and category cluster strategy, it will strengthen the company's competitive edge in chronic disease medications for the elderly and inject new momentum into performance growth. At the same time, the company cautioned that the launch and promotion of the drug are affected by multiple factors including national policies, market conditions, and corporate operating strategies, and that sales scale and performance outcomes remain uncertain.

Sunflower Pharmaceutical has decided to transfer its 10.3896% equity stake in Beijing Pharmastar Pharmaceutical Technology Co., Ltd. to Guangzhou Baiyunshan Heji Gong Pharmaceutical Co., Ltd. for 34.2858 million yuan. After the transfer, the company will no longer hold any equity in Pharmastar. The transaction price was determined through negotiation, referencing the appraised value of Pharmastar's entire equity at 332 million yuan. The company stated that this move aims to focus on its core business, concentrate on industry, and achieve investment recovery.

Sunflower Pharmaceutical announced the transfer of two investments on the same day. It sold a 10.3896 percent stake in Beijing Famaxing Pharmaceutical Technology Company to Guangzhou Baiyunshan Heji Gong Pharmaceutical Company for 34.285768 million yuan, and transferred its 1 million yuan capital contribution in Hangzhou Xiaochi Feihong Venture Capital Partnership to natural person Wu Mingxing for 1 million yuan. After the transactions, the company no longer holds any equity in the two entities. The company said the move aims to focus on its core business track of "the elderly, children, and women" and optimize its investment structure. In 2025, the company's full-year revenue was 2.318 billion yuan, down 31.36 percent year-on-year, and net profit attributable to the parent was negative 258 million yuan, down 152.40 percent year-on-year, marking the first operating loss in the company's 27-year history and 11 years as a listed company. Over the same period, selling expenses reached 580 million yuan, up 34.60 percent year-on-year, while research and development spending was 111 million yuan, down 10.49 percent year-on-year. In the first quarter of this year, the company achieved revenue of 844 million yuan, up 27.19 percent year-on-year, and net profit attributable to the parent of 110 million yuan, up 93.11 percent year-on-year.